hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Some of the functions of tears include lubricating the eyes (basal tears), removing irritants (reflex tears), and also aiding the immune system. Tears also occur as a part of the body's natural pain response. Emotional secretion of tears may serve a biological function by excreting stress-inducing hormones built up through times of emotional distress. Tears have symbolic significance among humans.
Depending on the venue's climate, the turf used was either a hybrid of 84% Kentucky bluegrass and 16% perennial ryegrass (for cooler temperatures), or Bermuda grass (for warmer temperatures). Four venues (Atlanta, Dallas, Houston, and Vancouver) were indoor stadiums that used retractable roof systems, all equipped with climate control, while a fifth, SoFi Stadium in Los Angeles, was open-air but had a translucent roof and no climate control. The host of the final match—MetLife Stadium in East Rutherford, New Jersey—was announced by FIFA on February 4, 2024. Although there were soccer-specific stadiums in Canada and the United States, the largest soccer-specific stadium in the U.S., Geodis Park in Nashville, Tennessee, seated 30,000, fell short of FIFA's minimum requirement of 40,000 seats (Toronto's BMO Field was expanded from 30,000 to 45,500 for this tournament). Stadiums including Mercedes-Benz Stadium in Atlanta; Gillette Stadium in Foxborough, Massachusetts; and Lumen Field in Seattle have been used by both National Football League (NFL) and Major League Soccer (MLS) teams. Although the Canadian and American stadiums were primarily used for gridiron football, they were also designed to accommodate soccer matches. Mexico City was the only capital of the three host nations chosen as a venue site; Ottawa and Washington, D.C., joined Bonn (West Germany, 1974) and Tokyo (Japan, 2002) as the only capital cities not selected to host World Cup matches.
=== Single-Crystal X-ray Diffraction === Single-crystal X-ray diffraction serves as the definitive method for determining atomic-level structure of organic cages. This technique provides precise information about spatial arrangements of atoms, revealing exact bond lengths, angles, and the three-dimensional architecture of the cage framework. Critical structural features such as cavity dimensions, shape, and packing arrangements in the solid state can be determined with high accuracy.
Sources: en.wikipedia.org
Solid-phase extraction (SPE) is a solid-liquid extractive technique, by which compounds that are dissolved or suspended in a liquid mixture are separated, isolated or purified, from other compounds in this mixture, according to their physical and chemical properties. Analytical laboratories use solid phase extraction to concentrate and purify samples for analysis. Solid phase extraction can be used to isolate analytes of interest from a wide variety of matrices, including urine, blood, water, beverages, soil, and animal tissue. SPE uses the affinity of solutes, dissolved or suspended in a liquid (known as the mobile phase), to a solid packing inside a small column, through which the sample is passed (known as the stationary phase), to separate a mixture into desired and undesired components. The result is that either the desired analytes of interest or undesired impurities in the sample are retained on the stationary phase. The portion that passes through the stationary phase is collected or discarded, depending on whether it contains the desired analytes or undesired impurities. If the portion retained on the stationary phase includes the desired analytes, they can then be removed from the stationary phase for collection in an additional step, in which the stationary phase is rinsed with an appropriate eluent. It is possible to have an incomplete recovery of the analytes by SPE caused by incomplete extraction or elution. In the case of an incomplete extraction, the analytes do not have enough affinity for the stationary phase and part of them will remain in the permeate.
After Harrison Stanford Martland (1883-1954), chief medical examiner in Essex County, detected the radioactive noble gas radon (a decay product of radium) in the breath of the Radium Girls, he turned to Charles Norris (1867-1935) and Alexander Oscar Gettler (1883-1968). In 1928, Gettler was able to detect a high concentration of radium in the bones of Amelia Maggia, one of the young women, even five years after her death. In 1931, a method was developed for determining radium dosage using a film dosimeter. A standard preparation is irradiated through a hardwood cube onto an X-ray film, which is then blackened. For a long time, the cube minute was an important unit of radium dosage. It was calibrated by ionometric measurements. The radiologists Hermann Georg Holthusen (1886-1971) and Anna Hamann (1894-1969) found a calibration value of 0.045 r/min in 1932/1935. The calibration film receives the y-ray dose of 0.045 r per minute through the wooden cube from the preparation of 13.33 mg. In 1933, the physicist Robley D. Evans (1907-1995) made the first measurements of radon and radium in the excretions of female workers. On this basis, the National Bureau of Standards, the predecessor to the National Institute of Standards and Technology (NIST), set the limit for radium at 0.1 microcuries (about 3.7 kilobecquerels) in 1941. A Radium Action Plan 2015-2019 aims to solve the problem of radiological contamination in Switzerland, mainly in the Jura Mountains, due to the use of radium luminous paint in the watch industry until the 1960s.
Ambrosiella roeperi is the fungal symbiont of the granulate ambrosia beetle, Xylosandrus crassiusculus, facilitating this insect's capacity to accumulate on and damage a diverse array of woody plants from around the world. It is one of several important nutritional partners derived from order Microascales that sustain and are transported by xylomycetophagous scolytine beetles.
Sources: en.wikipedia.org
The WHO Model List of Essential Medicines (a.k.a. Essential Medicines List or EML), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system. The list is frequently used by countries to help develop their own local lists of essential medicines. As of 2016, more than 155 countries have created national lists of essential medicines based on the World Health Organization's model list. This includes both developed and developing countries. The list is divided into core items and complementary items. The core items are deemed to be the most cost-effective options for key health problems and are usable with little additional health care resources. The complementary items either require additional infrastructure such as specially trained health care providers or diagnostic equipment or have a lower benefit–cost ratio. About 25% of items are in the complementary list. Some medications are listed as both core and complementary. While most medications on the list are available as generic products, being under patent does not prevent inclusion. The first list was published in 1977 and included 208 medications. The WHO updates the list every two years. There are 306 medications in the 14th list in 2005, 410 in the 19th list in 2015, 433 in the 20th list in 2017, 460 in the 21st list in 2019, and 479 in the 22nd list in 2021. Various national lists contain between 334 and 580 medications. The Essential Medicines List (EML) was updated in September 2025 to its 24th edition.
== Prognosis == Prognosis depends on the condition itself. Some conditions such as MS depend on the subtype of the disease and various attributes of the patient such as age, sex, initial symptoms, and the degree of disability the patient experiences. Life expectancy in MS patients is 5 to 10 years lower than unaffected people. MS is an inflammatory demyelinating disease of the central nervous system (CNS) that develops in genetically susceptible individuals after exposure to unknown environmental trigger(s). The bases for MS are unknown but are strongly suspected to involve immune reactions against autoantigens, particularly myelin proteins. The most accepted hypothesis is that dialogue between T-cell receptors and myelin antigens leads to an immune attack on the myelin-oligodendrocyte complex. These interactions between active T cells and myelin antigens provoke a massive destructive inflammatory response and promote continuing proliferation of T and B cells and macrophage activation, which sustains secretion of inflammatory mediators. Other conditions such as central pontine myelinolysis have about a third of patients recover and the other two-thirds experience varying degrees of disability. In some cases, such as transverse myelitis, the patient can begin recovery as early as 2 to 12 weeks after the onset of the condition.
EC 1.14.14.5: alkanesulfonate monooxygenase EC 1.14.14.6: Now EC 1.14.13.111, methanesulfonate monooxygenase EC 1.14.14.7: transferred to EC 1.14.19.9, tryptophan 7-halogenase EC 1.14.14.8: anthranilate 3-monooxygenase (FAD) EC 1.14.14.9: 4-hydroxyphenylacetate 3-monooxygenase EC 1.14.14.10: nitrilotriacetate monooxygenase EC 1.14.14.11: styrene monooxygenase EC 1.14.14.12: 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione monooxygenase EC 1.14.14.13: 4-(γ-L-glutamylamino)butanoyl-[BtrI acyl-carrier protein] monooxygenase EC 1.14.14.14: aromatase EC 1.14.14.15: (3S)-3-amino-3-(3-chloro-4-hydroxyphenyl)propanoyl-[peptidyl-carrier protein SgcC2] monooxygenase EC 1.14.14.16: steroid 21-monooxygenase EC 1.14.14.17: squalene monooxygenase EC 1.14.14.18: heme oxygenase (biliverdin-producing) EC 1.14.14.19: steroid 17α-monooxygenase EC 1.14.14.20: phenol 2-monooxygenase (FADH2) EC 1.14.14.21: dibenzothiophene monooxygenase EC 1.14.14.22: dibenzothiophene sulfone monooxygenase EC 1.14.14.23: cholesterol 7α-monooxygenase EC 1.14.14.24: vitamin D 25-hydroxylase EC 1.14.14.25: cholesterol 24-hydroxylase EC 1.14.14.26: 24-hydroxycholesterol 7α-hydroxylase EC 1.14.14.27: resorcinol 4-hydroxylase (FADH2) EC 1.14.14.28: long-chain alkane monooxygenase EC 1.14.14.29: 25/26-hydroxycholesterol 7α-hydroxylase EC 1.14.14.30: isobutylamine N-monooxygenase EC 1.14.14.31: ipsdienol synthase EC 1.14.14.32: 17α-hydroxyprogesterone deacetylase EC 1.14.14.33: ethylenediaminetetraacetate monooxygenase EC 1.14.14.34: methanesulfonate monooxygenase (FMNH2) EC 1.14.14.35: dimethylsulfone monooxygenase EC 1.14.14.36: tyrosine N-monooxygenase EC 1.14.14.37: 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.14.38: valine N-monooxygenase EC 1.14.14.39: isoleucine N-monooxygenase EC 1.14.14.40: phenylalanine N-monooxygenase EC 1.14.14.41: (E)-2-methylbutanal oxime monooxygenase EC 1.14.14.42: homomethionine N-monooxygenase EC 1.14.14.43: (methylsulfanyl)alkanaldoxime N-monooxygenase EC 1.14.14.44: phenylacetaldehyde oxime monooxygenase EC 1.14.14.45: aromatic aldoxime N-monooxygenase EC 1.14.14.46: pimeloyl-[acyl-carrier protein] synthase EC 1.14.14.47: nitric-oxide synthase (flavodoxin) EC 1.14.14.48: jasmonoyl-L-amino acid 12-hydroxylase EC 1.14.14.49: 12-hydroxyjasmonoyl-L-amino acid 12-hydroxylase EC 1.14.14.50: tabersonine 3-oxygenase EC 1.14.14.51: (S)-limonene 6-monooxygenase EC 1.14.14.52: (S)-limonene 7-monooxygenase EC 1.14.14.53: (R)-limonene 6-monooxygenase EC 1.14.14.54: phenylacetate 2-hydroxylase EC 1.14.14.55: quinine 3-monooxygenase EC 1.14.14.56: 1,8-cineole 2-exo-monooxygenase EC 1.14.14.57: taurochenodeoxycholate 6α-hydroxylase EC 1.14.14.58: trimethyltridecatetraene synthase EC 1.14.14.59: dimethylnonatriene synthase EC 1.14.14.60: ferruginol monooxygenase EC 1.14.14.61: carnosic acid synthase EC 1.14.14.62: salviol synthase EC 1.14.14.63: β-amyrin 16β-monooxygenase EC 1.14.14.64: β-amyrin 6β-monooxygenase EC 1.14.14.65: sugiol synthase EC 1.14.14.66: marmesin synthase EC 1.14.14.67: 11-hydroxysugiol 20-monooxygenase EC 1.14.14.68: syn-pimaradiene 3-monooxygenase EC 1.14.14.69: ent-cassadiene hydroxylase EC 1.14.14.70: ent-sandaracopimaradiene 3-hydroxylase EC 1.14.14.71: cucurbitadienol 11-hydroxylase EC 1.14.14.72: drimenol monooxygenase EC 1.14.14.73: albendazole monooxygenase (sulfoxide-forming) EC 1.14.14.74: albendazole monooxygenase (hydroxylating) EC 1.14.14.75: fenbendazole monooxygenase (4′-hydroxylating) EC 1.14.14.76: ent-isokaurene C2/C3-hydroxylase EC 1.14.14.77: phenylacetonitrile α-monooxygenase EC 1.14.14.78: phylloquinone ω-hydroxylase EC 1.14.14.79: docosahexaenoic acid ω-hydroxylase EC 1.14.14.80: long-chain fatty acid ω-monooxygenase EC 1.14.14.81: flavanoid 3′,5′-hydroxylase EC 1.14.14.82: flavonoid 3′-monooxygenase EC 1.14.14.83: geraniol 8-hydroxylase EC 1.14.14.84: linalool 8-monooxygenase EC 1.14.14.85: 7-deoxyloganate 7-hydroxylase EC 1.14.14.86: ent-kaurene monooxygenase EC 1.14.14.87: 2-hydroxyisoflavanone synthase EC 1.14.14.88: isoflavone 3′-hydroxylase EC 1.14.14.89: 4′-methoxyisoflavone 2′-hydroxylase EC 1.14.14.90: isoflavone 2′-hydroxylase EC 1.14.14.91: trans-cinnamate 4-monooxygenase EC 1.14.14.92: benzoate 4-monooxygenase EC 1.14.14.93: 3,9-dihydroxypterocarpan 6a-monooxygenase EC 1.14.14.94: leukotriene-B4 20-monooxygenase EC 1.14.14.95: germacrene A hydroxylase EC 1.14.14.96: 5-O-(4-coumaroyl)-D-quinate 3′-monooxygenase EC 1.14.14.97: methyltetrahydroprotoberberine 14-monooxygenase EC 1.14.14.98: protopine 6-monooxygenase EC 1.14.14.99: (S)-limonene 3-monooxygenase EC 1.14.14.100: dihydrosanguinarine 10-monooxygenase EC 1.14.14.101: dihydrochelirubine 12-monooxygenase EC 1.14.14.102: N-methylcoclaurine 3′-monooxygenase EC 1.14.14.103: tabersonine 16-hydroxylase EC 1.14.14.104: vinorine hydroxylase EC 1.14.14.105: taxane 10β-hydroxylase EC 1.14.14.106: taxane 13α-hydroxylase EC 1.14.14.107: ent-kaurenoic acid monooxygenase EC 1.14.14.108: 2,5-diketocamphane 1,2-monooxygenase EC 1.14.14.109: 3-hydroxyindolin-2-one monooxygenase EC 1.14.14.110: 2-hydroxy-1,4-benzoxazin-3-one monooxygenase EC 1.14.14.111: 9β-pimara-7,15-diene oxidase EC 1.14.14.112: ent-cassa-12,15-diene 11-hydroxylase EC 1.14.14.113: α-humulene 10-hydroxylase EC 1.14.14.114: amorpha-4,11-diene 12-monooxygenase EC 1.14.14.115: 11-oxo-β-amyrin 30-oxidase EC 1.14.14.116: averantin hydroxylase EC 1.14.14.117: aflatoxin B synthase EC 1.14.14.118: tryprostatin B 6-hydroxylase EC 1.14.14.119: fumitremorgin C monooxygenase EC 1.14.14.120: dammarenediol 12-hydroxylase EC 1.14.14.121: protopanaxadiol 6-hydroxylase EC 1.14.14.122: oryzalexin E synthase EC 1.14.14.123: oryzalexin D synthase EC 1.14.14.124: dihydromonacolin L hydroxylase EC 1.14.14.125: monacolin L hydroxylase EC 1.14.14.126: β-amyrin 28-monooxygenase EC 1.14.14.127: methyl farnesoate epoxidase EC 1.14.14.128: farnesoate epoxidase EC 1.14.14.129: long-chain acyl-CoA ω-monooxygenase EC 1.14.14.130: laurate 7-monooxygenase EC 1.14.14.131: bursehernin 5′-monooxygenase EC 1.14.14.132: (–)-4′-demethyl-deoxypodophyllotoxin 4-hydroxylase EC 1.14.14.133: 1,8-cineole 2-endo-monooxygenase EC 1.14.14.134: β-amyrin 24-hydroxylase EC 1.14.14.135: glyceollin synthase EC 1.14.14.136: deoxysarpagine hydroxylase EC 1.14.14.137: (+)-abscisic acid 8′-hydroxylase EC 1.14.14.138: lithocholate 6β-hydroxylase EC 1.14.14.139: 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.14.140: Now included with EC 1.14.14.162 EC 1.14.14.162, flavanone 2-hydroxylase EC 1.14.14.141: psoralen synthase EC 1.14.14.142: 8-dimethylallylnaringenin 2′-hydroxylase EC 1.14.14.143: (+)-menthofuran synthase EC 1.14.14.144: abieta-7,13-diene hydroxylase EC 1.14.14.145: abieta-7,13-dien-18-ol hydroxylase EC 1.14.14.146: geranylgeraniol 18-hydroxylase EC 1.14.14.147: 3-epi-6-deoxocathasterone 23-monooxygenase EC 1.14.14.148: angelicin synthase EC 1.14.14.149: 5-epiaristolochene 1,3-dihydroxylase EC 1.14.14.150: costunolide synthase EC 1.14.14.151: premnaspirodiene oxygenase EC 1.14.14.152: β-amyrin 11-oxidase EC 1.14.14.153: indole-2-monooxygenase EC 1.14.14.154: sterol 14α-demethylase EC 1.14.14.155: 3,6-diketocamphane 1,2-monooxygenase EC 1.14.14.156: tryptophan N-monooxygenase EC 1.14.14.157: indolin-2-one monooxygenase EC 1.14.14.158: carotenoid ε hydroxylase EC 1.14.14.159: dolabradiene monooxygenase EC 1.14.14.160: zealexin A1 synthase EC 1.14.14.161: nepetalactol monooxygenase EC 1.14.14.162: flavanone 2-hydroxylase EC 1.14.14.163: (S)-1-hydroxy-N-methylcanadine 13-hydroxylase EC 1.14.14.164: fraxetin 5-hydroxylase EC 1.14.14.165: indole-3-carbonyl nitrile 4-hydroxylase EC 1.14.14.166: (S)-N-methylcanadine 1-hydroxylase EC 1.14.14.167: (13S,14R)-13-O-acetyl-1-hydroxy-N-methylcanadine 8-hydroxylase EC 1.14.14.168: germacrene A acid 8β-hydroxylase EC 1.14.14.169: eupatolide synthase EC 1.14.14.170: 8-epi-inunolide synthase EC 1.14.14.171: β-amyrin 16α-hydroxylase EC 1.14.14.172: 3,5,6-trichloropyridin-2-ol monooxygenase EC 1.14.14.173: 2,4,6-trichlorophenol monooxygenase EC 1.14.14.174: geranylhydroquinone 3′′-hydroxylase EC 1.14.14.175: ferruginol synthase EC 1.14.14.176: taxadiene 5α-hydroxylase EC 1.14.14.177: ultra-long-chain fatty acid ω-hydroxylase EC 1.14.14.182: taxoid 7beta-hydroxylase EC 1.14.14.197: progesterone 11alpha-monooxygenase
===== Methods ===== Methods of functionalizing the 4RepCT protein have been successful, but not in the way of reliably producing a stable protein functionalization in biologic environments that can also be tuned and modified. Genetic fusion of functional peptide sequences to silk genes and chemical conjugation of functional molecules onto amino acid side chains are the only two methods currently known to achieve a functionalized 4RepCT protein with tunable functionality. The first approach has the advantage that post-translational manipulation of the silk is minimized. Unfortunately, genetic manipulation is challenging due to the high GC (guanine-cytosine) content of the gene which leads to transcription errors. This method also limits the prevalence of functional binding sites to a single ligand-binding site per 25 kDa 4RepCT silk protein. Large adaptor proteins such as antibodies can be used to display more binding sites, but it isn't considered a feasible solution. This method has been shown to produce 4RepCT proteins that have a higher cell adhesion than natural spidroin proteins and have varied antimicrobial properties. The second method, chemical modification of the silk proteins should result in the covalent attachment of several copies of a wide range of organic and organometallic ligands using robust or sensitive linkers depending on the application. The challenge with this method is it is difficult to make the modification of the 4RepCT protein site-specific.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.